PXS Stock Chart & Stats
€0.09
€0.01(5.22%)
At close: 4:00 PM EST
€0.09
€0.01(5.22%)
Day’s Range― - ―
52-Week Range€0.06 - €0.21
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€134.37M
Enterprise Value€722.97
Total Cash (Recent Filing)€30.86M
Total Debt (Recent Filing)€464.29M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,655,305,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)1.90
Price to Sales (P/S)0.17
P/FCF Ratio-26.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.10Price Target Upside15.72% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)€2.26B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue & ServicesParagon's mix of equipment sales plus recurring consumables and service contracts creates a more durable revenue base. Installed-equipment follow-on revenue and technical support drive customer stickiness, predictable aftermarket sales and cross-sell opportunities over coming quarters.
Manageable LeverageA sub-1.0 debt-to-equity ratio suggests the company is not over-levered, preserving financial flexibility. Manageable leverage reduces refinancing pressure, supports working-capital funding for distribution, and allows targeted investments in service capability without immediate solvency risk.
Improving Operating MarginsObserved EBIT/EBITDA margin improvements point to operational efficiencies and cost discipline. If sustained, these improvements can enhance cash generation per revenue dollar, partly offsetting low top-line growth and supporting longer-term profitability as volumes recover.
Bears Say
Sharp Revenue DeclineA large revenue drop reduces scale benefits and strains fixed-cost absorption for a distributor. Persistent top-line weakness undermines bargaining power with suppliers, limits reinvestment capacity, and makes margin recovery harder without structural demand improvements.
Low Gross MarginsSub-9% gross margins leave limited room to cover operating expenses and invest in growth. Low product-level profitability makes the business highly sensitive to price competition and cost inflation, forcing reliance on volume or higher-margin services to sustain net returns.
Negative Operating And Free Cash FlowNegative operating and free cash flow signals difficulty converting revenue into sustainable cash, pressuring liquidity and increasing reliance on external funding. Volatile cash metrics from a negative base limit capacity to finance working capital and service growth initiatives reliably.
Paragon Care Limited News
PXS FAQ
What was Paragon Care Limited’s price range in the past 12 months?
Paragon Care Limited lowest stock price was €0.06 and its highest was €0.21 in the past 12 months.
What is Paragon Care Limited’s market cap?
Paragon Care Limited’s market cap is €134.37M.
When is Paragon Care Limited’s upcoming earnings report date?
Paragon Care Limited’s upcoming earnings report date is Aug 27, 2026 which is in 34 days.
How were Paragon Care Limited’s earnings last quarter?
Paragon Care Limited released its earnings results on Feb 24, 2026. The company reported -€0.79 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Paragon Care Limited overvalued?
According to Wall Street analysts Paragon Care Limited’s price is currently Undervalued.
Does Paragon Care Limited pay dividends?
Paragon Care Limited does not currently pay dividends.
What is Paragon Care Limited’s EPS estimate?
Paragon Care Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paragon Care Limited have?
Paragon Care Limited has 1,655,305,400 shares outstanding.
What happened to Paragon Care Limited’s price movement after its last earnings report?
Paragon Care Limited reported an EPS of -€0.79 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.522%.
Which hedge fund is a major shareholder of Paragon Care Limited?
Currently, no hedge funds are holding shares in DE:PXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Paragon Care Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.10 (15.72% Upside)
€0.10 (15.72% Upside)
Blogger Sentiment
Bullish
DE:PXS Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €16.6K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.09%
Trailing 12-Months
Company Description
Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, breast milk tracking, electrodes; sterilisable transducers designed for surgical procedures, digital theatre integration, infection control, infusion therapy, temperature management, enteral feeding, pain management, lasers, operating room products, surgical consumables, and ultrasound systems. In addition, the company offers aesthetic devices for dermatologists, cosmetic surgeons, general practitioners, beauty and aesthetic providers, and educational institutions; natural, traditional, and complementary health products and services; critical care and dental solutions; urology solutions, such as shockwave therapy, lasers, and accessories for infection control; medical products and consumables; and orthopaedics solutions, including hip and knee arthroplasty, upper and lower extremity, sports medicine, reverse shoulder replacement, and powered surgical tools. Further, it offers medical equipment repair, maintenance, and support services; technology and communication solutions, such as telephony, nurse call, access control, cctv, cordless, and Wi-Fi; supplies medical equipment to veterans, war widows, and families; and veterinary products. Additionally, it is involved in maintenance of technical medical equipment to the health, aged care, and veterinary markets; and distribution of pharmaceuticals, medical consumables, and complementary medicines to Australian healthcare market. The company is based in Mount Waverley, Australia.
PXS Stock 12 Month Forecast
Average Price Target
€0.10
▲(15.72% Upside)
Technical Analysis
Sigma Healthcare Ltd
―
Polynovo
―
Compumedics Limited
―
Epsilon Healthcare Limited
―
Trajan Group Holdings Ltd
―